NeuroMetrix, Inc. (NURO)

USD 3.84

(3.5%)

Market Cap (In USD)

7.84 Million

Revenue (In USD)

5.9 Million

Net Income (In USD)

-6.52 Million

Avg. Volume

18.13 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.66-4.73
PE
-
EPS
-
Beta Value
2.301
ISIN
US6412558800
CUSIP
641255807
CIK
1289850
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Shai N. Gozani M.D., Ph.D.
Employee Count
-
Website
https://www.neurometrix.com
Ipo Date
2004-07-22
Details
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

More Stocks